Answers are grounded in this paper and cite their sources.
To build a more detailed understanding of the biological activity and binding interactions of PRX012, a next-generation, subcutaneously delivered anti-amyloid-beta (Aβ) monoclonal antibody (mAb) under investigation for the treatment of Alzheimer's disease (AD).
No takes yet. Share an insight, caveat, or question.
Campbell et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: